A strong interaction between serum γ-glutamyltransferase and obesity on the risk of prevalent type 2 diabetes: Results from the third national health and nutrition examination survey

Clinical Chemistry

Volumn 53, Issue 6, 2007, Pages 1092-1098

  Lim, Ji Sun ^a   Lee, Duk Hee ^a   Park, Joo Yun ^a   Jin, Soo Hee ^a   Jacobs Jr , David R ^b,c  

^a Kyungpook National University School of Medicine   (South Korea)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE;

ADULT; BODY MASS; CLINICAL ASSESSMENT TOOL; DISEASE ASSOCIATION; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEALTH SURVEY; HIGH RISK POPULATION; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; REVIEW; RISK FACTOR; STATISTICAL ANALYSIS;

ADULT; AGE FACTORS; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY; PREDICTIVE VALUE OF TESTS; PREVALENCE; RISK; SERUM;

EID: 34249931199     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.079814     Document Type: Review

References (23)

1. Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci 2001;38:263-355.
2. Nilssen O, Forde OH, Brenn T. The Tromso Study: distribution and population determinants of gamma-glutamyltransferase. Am J Epidemiol 1990;132:318-26.
3. Wannamethee G, Ebrahim S, Shaper AG. Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol 1995;142:699-708.
4. Brenner H, Rothenbacher D, Amdt V, Schuberth S, Fraisse E, Fliedner TM. Distribution, determinants, and prognostic value of gamma-glutamyltransferase for all-cause mortality in a cohort of construction workers from southern Germany. Prev Med 1997;26: 305-10.
5. Perry IJ, Wannamethee SG, Shaper AG. Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care 1998;21:732-7.
6. Miura K, Nakagawa H, Nakamura H, Tabata M, Nagase H, Yoshida M, et al. Serum gamma-glutamyl transferase level in predicting hypertension among male drinkers. J Hum Hypertens 1994;8: 445-9.
7. Jousilahti P, Rastenyte D, Tuomilehto J. Serum gamma-glutamyl transferase, self-reported alcohol drinking, and the risk of stroke. Stroke 2000;31:1851-5.
8. Lee DH, Ha MH, Kim JH, Christiani DC, Gross MD, Steffes M, et al. Gamma-glutamyltransferase and diabetes-A 4 year follow-up study. Diabetologia 2003;46:359-64.
9. Lee DH, Jacobs DR, Gross M, Kiefe CI, Roseman J, Lewis CE, et al. Gamma glutamyltransferase is a predictor of incident diabetes and hypertension: the CARDIA Study. Clin Chem 2003;49:1358-66.
10. Lee DH, Silventoinen K, Jacobs DR Jr, Jousilahti P, Tuomileto J. Gamma-glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women. J Clin Endocrinol Metab 2004;89:5410-4.
11. Andre P, Balkau B, Bom C, Charles MA, Eschwege E, D.E.S.I.R. Study Group. Three-year increase of gamma-glutamyltransferase level and development of type 2 diabetes in middle-aged men and women: the D.E.S.I.R. cohort. Diabetologia 2006;49:2599-603.
12. Nannipieri M, Gonzales C, Baldi S, Posadas R, Williams K, Haffner SM, et al. Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care 2005; 28:1757-62.
13. Meisinger C, Lowel H, Heier M, Schneider A, Thorand B. KORA Study Group: serum gamma-glutamyltransferase and risk of type 2 diabetes mellitus in men and women from the general population. J Intern Med 2005;258:527-35.
14. Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H. Vorarlberg Health Monitoring and Promotion Program Study Group: gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 2005;112:2130-7.
15. King, H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025. Diabetes Care 1998;21:1414-31.
16. Mensah GA, Mokdad AH, Ford E, Narayan KM, Giles WH, Vinicor F, et al. Obesity, metabolic syndrome, and type 2 diabetes: emerging epidemics and their cardiovascular implications. Cardiol Clin 2004;22:485-604.
17. National Center for Health Statistics, US Department of Health and Human Services. Third National Health and Nutrition Examination Survey, 1988-1994. References, manuals and reports (CD-ROM). Hyattsville, MD: Centers for Disease Control and Prevention, 1996.
18. Kom EL, Graubard BI. Epidemiologic studies utilizing surveys: accounting for the sampling design. Am J Public Health 1991;81: 1166-73.
19. Graubard BI, Kom EL. Analyzing health surveys for cancer-related objectives. J Natl Cancer Inst 1999;91:1005-16.
20. Brunt EM. Nonalcoholic steatohepatitis. Samin Liver Dis 2004; 24:3-20.
21. Yu AS, Keeffe EB. Elevated AST or ALT to nonalcoholic fatty liver disease: accurate predictor of disease prevalence? Am J Gastroenterol 2003;98:955-6.
22. Lee DH, Lee IK, Song KE, Steffes M, Toscano W, Baker BA, et al. A strong dose-response relation between serum concentrations of Persistent Organic Pollutants and diabetes: results from the National Health and Examination Survey. Diabetes Care 2006;29: 1638-44.
23. Lee DH, Jacobs DR. Association between serum concentrations of persistent organic pollutants and gamma glutamyltransferase: results from the National Health and Examination Survey 1999-2002. Clin Chem 2006;52:1825-7.